Joint PhRMA - BIO Letter on IPR

PhRMA and Epilepsy Foundation Report More Than 400 Medicines in Development to Treat Neurological Disorders

Washington, D.C. (July 13, 2015) — America’s biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer’s disease, multiple sclerosis (MS) and Parkinson’s disease.

Neurological drug list

PhRMA Cures Letter of Support

Innovation in the Biopharmaceutical R&D Process – Adapting to a Changing Environment

This backgrounder looks at the strategies and tactics biopharmaceutical companies have implemented to adapt to evolving trends in the research and development (R&D) process. While the last five years have been among the most productive in history for new drug approvals and innovation, this remarkable progress follows a decade of reduced productivity levels.

The Value of Innovation in Oncology - Recognizing Emerging Benefits Over Time Executive Summary

Biopharmaceutical Companies Driving Personalized Medicine

Research in Pennsylvania

Sens. Portman, Cornyn, et al letter

Morning Consult - PhRMA National Poll - 5.1.15


Subscribe to RSS - Innovation